|
gptkbp:instanceOf
|
gptkb:antiarrhythmic_drug
gptkb:drug
|
|
gptkbp:approvalYear
|
2009
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
C01BD07
|
|
gptkbp:bioavailability
|
4%
|
|
gptkbp:brand
|
gptkb:Multaq
|
|
gptkbp:CASNumber
|
141625-93-6
|
|
gptkbp:contraindication
|
gptkb:second-_or_third-degree_AV_block
severe heart failure
QT interval prolongation
liver impairment
permanent atrial fibrillation
|
|
gptkbp:developedBy
|
gptkb:Sanofi-Aventis
|
|
gptkbp:drugClass
|
Class III antiarrhythmic
|
|
gptkbp:eliminationHalfLife
|
13-19 hours
|
|
gptkbp:excretion
|
fecal
renal (minor)
|
|
gptkbp:hasBoxedWarning
|
increased risk of death in patients with decompensated heart failure or permanent atrial fibrillation
|
|
gptkbp:hasMolecularFormula
|
C31H44N2O5S
|
|
gptkbp:KEGGID
|
D08913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits potassium, sodium, and calcium channels
multichannel blocker
non-competitive antiadrenergic activity
|
|
gptkbp:metabolism
|
hepatic (CYP3A4)
|
|
gptkbp:molecularWeight
|
556.76 g/mol
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
|
|
gptkbp:proteinBinding
|
>98%
|
|
gptkbp:PubChem_CID
|
CHEMBL1201192
181003
208902
DB04855
|
|
gptkbp:relatedTo
|
amiodarone
|
|
gptkbp:riskFactor
|
pulmonary toxicity
liver injury
worsening heart failure
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
rash
bradycardia
increased serum creatinine
|
|
gptkbp:UNII
|
VW5QM6VPK8
|
|
gptkbp:usedFor
|
gptkb:atrial_fibrillation
atrial flutter
|
|
gptkbp:bfsParent
|
gptkb:CYP3A5
gptkb:Multaq
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dronedarone
|